Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Breakthrough Device Designation lifts Neola shares

7 September 2026 · By · Wire by Fusion42

Published

7 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at lifesciencenordic.com →

◆ Verified

Fusion42 · 7 September 2026 · Fusion42 review

Neola Medical, a Lund-based company, received the FDA Breakthrough Device Designation for its continuous lung monitoring device for preterm infants, causing a surge in its shares.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

FDA's breakthrough designation for Neola's lung monitor opens US market doors for you in neonatal care, accelerating approval and adoption timelines. You can use this to target hospitals needing cutting-edge solutions for preterm infant care.

◆ Coverage

1 source · 7 Sep 2026

◆ Related on Wire

◆ Topics

Medtechfdamedical-devicepreterm-infantslung-monitoringregulatory-approval